| Drugs by Condition |  |
Gout Medications
Definition of Gout: Gout is one of the most common forms of arthritis (joint inflammation). It appears as an acute attack. Within 12-24 hours of the attack, there is severe pain and swelling in the affected joint. Gout usually affects only one joint at a time - most often the feet and ankles. The joints in the big toe are common sites.
Drugs (by generic name) associated with Gout
The following drugs and medications are in some way related to, or used in the treatment of Gout. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
probenecid systemic (Pro, More...) class: antigout agents | 1 review(s) |  | 9.0 | |
| febuxostat systemic (Pro, More...)class: antigout agents, antihyperuricemic agents | 3 review(s) | | 8.3 | |
| allopurinol systemic (Pro, More...)class: antigout agents, antihyperuricemic agents | 4 review(s) | | 7.8 | |
See also...
Gout Medications in the Pipeline
- June 24, 2004 - Cardiome Receives FDA Approvable Letter on Oxypurinol for Gout
- March 9, 2004 - Oxypurinol Regulatory Filing Accepted for Review
- September 19, 2009 - Savient Provides Update on Meeting with U.S. Food and Drug Administration for Krystexxa
- August 4, 2009 - Savient Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Krystexxa
- June 17, 2009 - FDA Appointed Arthritis Advisory Committee Recommends U.S. Food and Drug Administration Approval for Krystexxa for Refractory Chronic Gout
- May 7, 2009 - Savient Announces New Date for FDA Arthritis Advisory Panel Review of Krystexxa for Treatment Failure Gout
- February 12, 2009 - Savient Provides Update on Pegloticase BLA
- January 28, 2009 - Savient Announces FDA's Advisory Panel to Review Pegloticase for Treatment-Failure Gout Patients
- December 30, 2008 - Pegloticase BLA Filing Accepted for Priority Review by FDA
- October 31, 2008 - Savient Submits Biologics License Application (BLA) for Pegloticase
Latest Gout Blog Post
Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594
86% Response Rate in Gout Patients After Eight Days of Treatment
SAN DIEGO--(BUSINESS WIRE)--Jun 11, 2009 - Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594, its...
View all Gout blog posts.
Gout Support Group Questions
Go to the Gout support group or view all Gout questions.
Ask a Question about Gout:
Learn more about Gout
Medical encyclopedia results for:
